Cancer Metastasis

Submission Deadline: 31 December 2023 Submit to Special Issue

Guest Editors

Aamir Ahmad, Translational Research Institute, Hamad Medical Corporation, Qatar. Email: Aahmad9@hamad.qa

Summary

Metastasis of primary tumors to distant organs is the major reason for cancer-associated mortality. Recent advancements have provided some mechanistic insights but the information is far from definite and the clinical management of patients remains dismal, thus underlying the need for more concerted efforts to better understand the process and identify and validate putative targets for therapy. A number of factors, including growth factors, chemokines, cytokines etc. have been linked with cancer metastasis, as also several non-coding RNAs, such as, microRNAs, long non-coding RNAs, circular RNAs etc. Further, several cellular signaling pathways, transcription factors and the acquisition of cancer stem cells phenotype and epithelial-to-mesenchymal transition also have a role to play in cancer metastasis. The characterization of in vivo metastasis models has helped evolve the field and the clinical evaluations of patients-derived samples have helped list many potential metastasis-related biomarkers. This special issue on Cancer Metastasis invites articles on all different aspects that define the complexity of the phenomenon and may contribute towards a better understanding of the subject and/or identify/validate targets for therapy.


Keywords

Cancer Metastasis; Cytokines; Growth factors; Non-coding RNAs; Cancer stem cells; Epithelial-to-mesenchymal transition; Biomarkers

Published Papers


  • Open Access

    ARTICLE

    ELK3-ID4 axis governs the metastatic features of triple negative breast cancer

    JIN-HO CHOI, JOO DONG PARK, SEUNG HEE CHOI, EUN-SU KO, HYE JUNG JANG, KYUNG-SOON PARK
    Oncology Research, Vol.32, No.1, pp. 127-138, 2024, DOI:10.32604/or.2023.042945
    (This article belongs to this Special Issue: Cancer Metastasis)
    Abstract Purpose: Cancer cell metastasis is a multistep process, and the mechanism underlying extravasation remains unclear. ELK3 is a transcription factor that plays a crucial role in regulating various cellular processes, including cancer metastasis. Based on the finding that ELK3 promotes the metastasis of triple-negative breast cancer (TNBC), we investigated whether ELK3 regulates the extravasation of TNBC by forming the ELK3-ID4 axis. ID4 functions as a transcriptional regulator that interacts with other transcription factors, inhibiting their activity and subsequently influencing various biological processes associated with cell differentiation, survival, growth, and metastasis. Methods: We assessed the correlation between the expression of ELK3… More >

    Graphic Abstract

    ELK3-ID4 axis governs the metastatic features of triple negative breast cancer

  • Open Access

    ARTICLE

    Deciphering key genes involved in cisplatin resistance in kidney renal clear cell carcinoma through a combined in silico and in vitro approach

    MUNEEBA MALIK, MAMOONA MAQBOOL, TOOBA NISAR, TAZEEM AKHTER, JAVED AHMED UJAN, ALANOOD S. ALGARNI, FAKHRIA A. AL JOUFI, SULTAN SHAFI K. ALANAZI, MOHAMMAD HADI ALMOTARED, MOUNIR M. SALEM BEKHIT, MUHAMMAD JAMIL
    Oncology Research, Vol.31, No.6, pp. 899-916, 2023, DOI:10.32604/or.2023.030760
    (This article belongs to this Special Issue: Cancer Metastasis)
    Abstract The low survival rate of Kidney renal clear cell carcinoma (KIRC) patients is largely attributed to cisplatin resistance. Rather than focusing solely on individual proteins, exploring protein-protein interactions could offer greater insight into drug resistance. To this end, a series of in silico and in vitro experiments were conducted to identify hub genes in the intricate network of cisplatin resistance-related genes in KIRC chemotherapy. The genes involved in cisplatin resistance across KIRC were retrieved from the National Center for Biotechnology Information (NCBI) database using search terms as “Kidney renal clear cell carcinoma” and “Cisplatin resistance”. The genes retrieved were analyzed… More >

  • Open Access

    ARTICLE

    Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma

    WENHAO XU, HAOMING LI, YASIR HAMEED, MOSTAFA A. ABDEL-MAKSOUD, SAEEDAH MUSAED ALMUTAIRI, AYMAN MUBARAK, MOHAMMED AUFY, WAEL ALTURAIKI, ABDULAZIZ J. ALSHALANI, AYMAN M. MAHMOUD, CHEN LI
    Oncology Research, Vol.31, No.5, pp. 819-831, 2023, DOI:10.32604/or.2023.029414
    (This article belongs to this Special Issue: Cancer Metastasis)
    Abstract N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score to assess the alteration pattern… More >

Share Link